640 related articles for article (PubMed ID: 16877425)
21. Progression of hydroxychloroquine toxic effects after drug therapy cessation: new evidence from multimodal imaging.
Mititelu M; Wong BJ; Brenner M; Bryar PJ; Jampol LM; Fawzi AA
JAMA Ophthalmol; 2013 Sep; 131(9):1187-97. PubMed ID: 23887202
[TBL] [Abstract][Full Text] [Related]
22. Abnormal fundus autofluorescence results of patients in long-term treatment with deferoxamine.
Viola F; Barteselli G; Dell'arti L; Vezzola D; Villani E; Mapelli C; Zanaboni L; Cappellini MD; Ratiglia R
Ophthalmology; 2012 Aug; 119(8):1693-700. PubMed ID: 22480740
[TBL] [Abstract][Full Text] [Related]
23. Evaluation of Retromode Imaging for Use in Hydroxychloroquine Retinopathy.
Ahn SJ; Lee SU; Lee SH; Lee BR
Am J Ophthalmol; 2018 Dec; 196():44-52. PubMed ID: 30118686
[TBL] [Abstract][Full Text] [Related]
24. Revised recommendations on screening for chloroquine and hydroxychloroquine retinopathy.
Marmor MF; Kellner U; Lai TY; Lyons JS; Mieler WF;
Ophthalmology; 2011 Feb; 118(2):415-22. PubMed ID: 21292109
[TBL] [Abstract][Full Text] [Related]
25. Impact of the revised american academy of ophthalmology guidelines regarding hydroxychloroquine screening on actual practice.
Browning DJ
Am J Ophthalmol; 2013 Mar; 155(3):418-428.e1. PubMed ID: 23218706
[TBL] [Abstract][Full Text] [Related]
26. Fluorescence Lifetimes in Patients With Hydroxychloroquine Retinopathy.
Solberg Y; Dysli C; Möller B; Wolf S; Zinkernagel MS
Invest Ophthalmol Vis Sci; 2019 May; 60(6):2165-2172. PubMed ID: 31108547
[TBL] [Abstract][Full Text] [Related]
27. Fundus autofluorescence and multiple evanescent white dot syndrome.
Furino C; Boscia F; Cardascia N; Alessio G; Sborgia C
Retina; 2009 Jan; 29(1):60-3. PubMed ID: 18936716
[TBL] [Abstract][Full Text] [Related]
28. FUNDUS AUTOFLUORESCENCE FINDINGS IN EARLY CHLOROQUINE MACULOPATHY.
Bergholz R; Rossel M; Schroeter J; Dutescu RM; Salchow DJ
Retin Cases Brief Rep; 2018 Spring; 12(2):81-86. PubMed ID: 27768637
[TBL] [Abstract][Full Text] [Related]
29. Use of microperimetry to evaluate hydroxychloroquine and chloroquine retinal toxicity.
Martínez-Costa L; Victoria Ibañez M; Murcia-Bello C; Epifanio I; Verdejo-Gimeno C; Beltrán-Catalán E; Marco-Ventura P
Can J Ophthalmol; 2013 Oct; 48(5):400-5. PubMed ID: 24093187
[TBL] [Abstract][Full Text] [Related]
30. Disparity between visual fields and optical coherence tomography in hydroxychloroquine retinopathy.
Marmor MF; Melles RB
Ophthalmology; 2014 Jun; 121(6):1257-62. PubMed ID: 24439759
[TBL] [Abstract][Full Text] [Related]
31. Imaging of Hydroxychloroquine Toxicity with Fluorescence Lifetime Imaging Ophthalmoscopy.
Sauer L; Calvo CM; Vitale AS; Henrie N; Milliken CM; Bernstein PS
Ophthalmol Retina; 2019 Oct; 3(10):814-825. PubMed ID: 31345727
[TBL] [Abstract][Full Text] [Related]
32. Electrophysiological assessment for early detection of retinal dysfunction in β-thalassemia major patients.
Dettoraki M; Kattamis A; Ladas I; Maragkos K; Koutsandrea C; Chatzistefanou K; Laios K; Brouzas D; Moschos MM
Graefes Arch Clin Exp Ophthalmol; 2017 Jul; 255(7):1349-1358. PubMed ID: 28361176
[TBL] [Abstract][Full Text] [Related]
33. Evaluation of Hydroxychloroquine Retinopathy Using Ultra-Widefield Fundus Autofluorescence: Peripheral Findings in the Retinopathy.
Ahn SJ; Joung J; Lee BR
Am J Ophthalmol; 2020 Jan; 209():35-44. PubMed ID: 31526798
[TBL] [Abstract][Full Text] [Related]
34. LONGITUDINAL CHANGES IN EYES WITH HYDROXYCHLOROQUINE RETINAL TOXICITY.
Allahdina AM; Chen KG; Alvarez JA; Wong WT; Chew EY; Cukras CA
Retina; 2019 Mar; 39(3):473-484. PubMed ID: 30741731
[TBL] [Abstract][Full Text] [Related]
35. Retina in rheumatic diseases: standard full field and multifocal electroretinography in hydroxychloroquine retinal dysfunction.
Nebbioso M; Livani ML; Steigerwalt RD; Panetta V; Rispoli E
Clin Exp Optom; 2011 May; 94(3):276-83. PubMed ID: 20533929
[TBL] [Abstract][Full Text] [Related]
36. Missing the bull's eye.
Gilbert ME; Savino PJ
Surv Ophthalmol; 2007; 52(4):440-2. PubMed ID: 17574068
[TBL] [Abstract][Full Text] [Related]
37. Long-Term Progression of Pericentral Hydroxychloroquine Retinopathy.
Ahn SJ; Seo EJ; Kim KE; Kim YJ; Lee BR; Kim JG; Yoon YH; Lee JY
Ophthalmology; 2021 Jun; 128(6):889-898. PubMed ID: 33129843
[TBL] [Abstract][Full Text] [Related]
38. Evaluation of a follow-up protocol for patients on chloroquine and hydroxychloroquine treatment.
Sanabria MR; Toledo-Lucho SC
Arch Soc Esp Oftalmol; 2016 Jan; 91(1):10-4. PubMed ID: 26627497
[TBL] [Abstract][Full Text] [Related]
39. [Routine monitoring of patients treated with synthetic antimalarials].
Douche C; Bechetoille A; Ebran JM
J Fr Ophtalmol; 1983; 6(8-9):689-95. PubMed ID: 6677659
[TBL] [Abstract][Full Text] [Related]
40. Fundus autofluorescence imaging: review and perspectives.
Schmitz-Valckenberg S; Holz FG; Bird AC; Spaide RF
Retina; 2008 Mar; 28(3):385-409. PubMed ID: 18327131
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
